Phase 1 combination
Showing 1 - 25 of >10,000
IDH1-mutant Cholangiocarcinoma Trial (Ivosidenib, Recommended Combination Dose (RCD) of ivosidenib, Nivolumab)
Not yet recruiting
- IDH1-mutant Cholangiocarcinoma
- Ivosidenib
- +3 more
- (no location specified)
Jun 29, 2023
NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)
Not yet recruiting
- Non-small Cell Lung Cancer
- +4 more
- MK-2870
- +2 more
- (no location specified)
Sep 15, 2023
Locally Advanced Unresectable or Metastatic Esophageal Cancer Trial (Futibatinib, Pembrolizumab, Cisplatin)
Not yet recruiting
- Locally Advanced Unresectable or Metastatic Esophageal Cancer
- Futibatinib
- +6 more
- (no location specified)
Jul 6, 2023
Ovarian Cancer, Melanoma, Triple Negative Breast Cancer Trial (NM1F Injection, Pembrolizumab injection)
Not yet recruiting
- Ovarian Cancer
- +3 more
- NM1F Injection
- Pembrolizumab injection
- (no location specified)
Feb 23, 2023
MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors Trial (AMG 193, IDE397)
Not yet recruiting
- MTAP-null Non-Small-Cell Lung Cancer
- MTAP-null Solid Tumors
- AMG 193
- IDE397
- (no location specified)
Jul 27, 2023
Acute Myeloid Leukemia Trial in Houston (ASTX727, ASTX029-01)
Not yet recruiting
- Acute Myeloid Leukemia
-
Houston, TexasMD Anderson Cancer Center
Oct 27, 2023
Double Hit Lymphoma, Triple Hit Lymphoma Trial in Hangzhou (Selinexor+RCHOP)
Recruiting
- Double Hit Lymphoma
- Triple Hit Lymphoma
-
Hangzhou, Zhenjiang, ChinaZhejiang Cancer Hospital
Aug 2, 2023
Colorectal Cancer Trial in Hangzhou (Ametumumab, Anti-PD-1 mAb, Cetuximab)
Not yet recruiting
- Colorectal Cancer
- Ametumumab
- +3 more
-
Hangzhou, Zhejiang, ChinaSir Run Run Shaw Hospital, Zhejiang University School of Medicin
Jan 30, 2023
Cholangiocarcinoma Trial (GNS561 + Trametinib)
Not yet recruiting
- Cholangiocarcinoma
- GNS561 + Trametinib
- (no location specified)
May 22, 2023
Gastric Cancer, Peritoneal Metastases, Ascites, Malignant Trial in Hangzhou (Sintilimab in Combination With S-1/oxaliplatin With
Recruiting
- Gastric Cancer
- +2 more
- Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion
- Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Sep 18, 2023
Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer Trial (HST-1011, Cemiplimab)
Not yet recruiting
- Solid Tumor, Adult
- +2 more
- HST-1011
- Cemiplimab
- (no location specified)
Dec 14, 2022
Recurrent Ovarian Cancer, Recurrent Uterine Cancer, Metastatic Cancer Trial in Toronto (RP-6306, Carboplatin, Paclitaxel)
Not yet recruiting
- Recurrent Ovarian Cancer
- +3 more
- RP-6306
- +2 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Oct 25, 2023
Advanced Solid Tumors Trial in Canada, United States (LCB84, Anti-PD-1 mAb)
Not yet recruiting
- Advanced Solid Tumors
- LCB84
- Anti-PD-1 monoclonal antibody
-
Los Angeles, California
- +6 more
Jul 4, 2023
Non Small Cell Lung Cancer Recurrent Trial (Toripalimab, Anlotinib and Chemotherapy)
Not yet recruiting
- Non Small Cell Lung Cancer Recurrent
- Toripalimab, Anlotinib and Chemotherapy
- (no location specified)
Apr 24, 2023
Advanced or Metastatic Solid Tumors Trial (PMC-309 monotherapy, PMC-309 Dose Escalation in Combination with Pembrolizumab,
Not yet recruiting
- Advanced or Metastatic Solid Tumors
- PMC-309 monotherapy
- +2 more
- (no location specified)
Jul 19, 2023
Acute Myeloid Leukemia (AML) Trial in Nantes (Tocilizumab)
Active, not recruiting
- Acute Myeloid Leukemia (AML)
-
Nantes, FranceCHU of Nantes
Dec 16, 2022